An observational study in Bone and Joint Infection, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by Hospices Civils de Lyon · Observational
The malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. To our knowledge, there are few data and it is not wellc known byclinicians. Nevertheless it exposes to neurological complications potentially serious and crippling.
80 studies on the registry are indexed under Otitis; 10 are open to participants now.
This study's enrollment of 53 is below the median of 177 across 26 observational studies indexed under Otitis.
Browse Otitis studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients having had necrotizing external otitis and managed at the Lyon Bone and joint infection refence Center between 01/01/2006 and 31/01/2018
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
description of necrotizing external otitis
Other: necrotizing external otitis
description of necrotizing external otitis
Rate of necrotizing external otitis
description of necrotizing external otitis: patients, profile of the bacterium, medical and chirurgical treatment, rate
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Rate of Treatment Failure
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor.
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Duration of antibiotics
Description of the strategies of antibiotic treatments used (double-agent therapy, monotherapy, duration)
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2006 to primary completion in Jan 2018, 144 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.